Modulight as an investment
Modulight Corporation is a biomedical company that designs and manufactures laser devices for the treatment of cancer and eye diseases and for genetics. The company also manufactures products for other high-value applications such as quantum computing.
In January 2023, Modulight Corporation received the PMA (premarket approval) from the U.S. Food and Drug Administration (FDA) for its ML6710i laser device for the treatment of wet age-related macular degeneration (AMD) in the United States.
In 2022, Modulight’s revenue was EUR 4.6 million. The company’s EBITDA in 2022 was EUR -5.9 million and the EBITDA margin was -129.1 percent.
Expert in lasers and optics
years of experience in medical applications, the development and manufacture of lasers and optics
in total more than ten international pharmaceutical companies and Fortune 500 listed companies as customers
projects ongoing at the end of 2022, share of large multinational companies grew
In January 2023, market authorization from the U.S. Food and Drug Administration (FDA) for Modulight’s ML6710i laser device for treatment of wet age-related macular degeneration (AMD)